60-day pilot for qualified pathology, diagnostics, and research teams

Turn hematology files into review-ready evidence.

NanoCure AI helps pathologists, diagnostic teams, and researchers organize blood smear morphology and Flow Cytometry FCS files into one structured case workspace — including broad malignant/blast-like morphology review across AML, ALL, CML, CLL, and MDS workflows, without claiming subtype-specific diagnosis.

Request 60-Day Pilot Open Portal See the value

Research and workflow evaluation only. NanoCure AI organizes evidence for qualified reviewers and does not provide a final diagnosis, FDA-cleared diagnostic output, or replacement for pathologist interpretation.

No hardware swapWorks with existing image and FCS workflows.

One case viewMorphology + Flow evidence in a unified workspace.

Heme screenBroad AML/ALL/CML/CLL/MDS malignancy-group morphology review.

Exportable packetsStructured evidence for QA, research, validation, and handoff.

Hematology case evidence packet

Drop one case folder

peripheral_smear_slide_A01.tifMorphology

tube_03_blast_panel.fcsFlow FCS

case_evidence_packet.zipExport ready

Morphology

Cells mapped back to slide

Review crops, cell-level calls, case totals, and source-image context.

Flow FCS

Candidate population review

Inspect plots, marker context, candidate gates, and review notes.

The core value: fewer disconnected screenshots, spreadsheets, folders, and manual handoffs. More structured evidence for AML, ALL, CML, CLL, and MDS-related morphology review — with subtype interpretation kept with the reviewer.

The value add

Hematology review is not just one file. It is evidence assembly.

Pathologists and diagnostic teams already have the expertise. The bottleneck is that smear images, FCS files, plots, cell crops, screenshots, notes, and review decisions are scattered. NanoCure AI is built to turn AML, ALL, CML, CLL, MDS, and Flow Cytometry review workflows into a structured, auditable evidence environment.

Without NanoCure AI

×Technologists and reviewers move between folders, microscope images, FCS tools, screenshots, and notes.

×Pathologists spend time locating representative cells and reconciling disconnected evidence.

×QA, second review, research review, and handoff require manual packaging.

×Model outputs can be hard to audit if they are not tied back to source cells, plots, and reviewer decisions.

With NanoCure AI

✓One case workspace connects morphology images, FCS files, review actions, and exportable evidence.

✓Per-cell crops and calls are mapped back to the source slide for faster review and adjudication.

✓Flow plots and candidate populations sit beside morphology context instead of living in a separate silo.

✓Review decisions become structured data for QA, workflow validation, research, and future model improvement.

Production workflow

One workflow. Multiple evidence streams.

Designed around the way hematology evidence is actually reviewed: case first, modality second, reviewer always in control.

Ingest

Drop smear images and FCS files into a case folder or upload through the web portal.

Route

The platform separates morphology, heme-screen morphology, AML-only morphology, and Flow FCS workflows.

Structure

Cells, source images, plots, populations, case totals, and artifacts are organized into review panels.

Review

Pathologists and qualified reviewers accept, reject, correct, and annotate evidence.

Export

Generate case evidence packets for QA, research, workflow evaluation, collaboration, or handoff.

Software modules

Built for evidence review, not black-box automation.

NanoCure AI keeps the reviewer in the loop and makes the evidence easier to inspect, organize, export, and compare.

Heme Malignancy Screen

Broad malignant/blast-like morphology screening across AML, ALL, CML, CLL, and MDS workflows. This is a malignancy-group screen, not a subtype-specific diagnosis.

AML/ALL/CML/CLL/MDS grouped morphology support
Case-level screen totals
Per-cell crops, probabilities, and reviewer actions

AML

AML-only Morphology Review

Validated AML-focused workflow preserved separately for AML morphology review and patient-slide testing workflows.

AML-only path kept isolated
Per-cell slide mapping
Source-image traceability

Flow FCS Review

Turn FCS files into review-ready dot plots, candidate populations, marker context, and exportable Flow evidence.

Per-FCS linked graph review
Candidate population context
QC and review notes

APP

Desktop Lab Bridge

A Windows/Linux watch-folder agent routes case files to the correct workflow without forcing diagnostic teams to live inside the browser.

DATA

Review Data Layer

Structured review labels, cell crops, FCS context, source links, and artifact metadata create a foundation for QA, validation, research, and model improvement.

H&E

Histology Review Coming soon

Histology support is in development for whole-slide/tile review workflows, beginning with research-focused H&E tissue morphology organization and evidence packet generation.

Who should use it

Clear value for every reviewer in the hematology workflow.

Pathologists

Review organized evidence instead of hunting across images, plots, folders, screenshots, and notes.

Value

Faster review, better traceability, and cleaner case handoff.

Diagnostic technologists

Use the platform to route case files, prepare review packets, and surface AML/ALL/CML/CLL/MDS-group morphology cells and Flow populations that need attention.

Value

Less manual assembly and fewer disconnected review artifacts.

Lab directors

Evaluate AI workflow support while preserving current microscopes, cameras, scanners, and flow cytometers.

Value

Operational visibility, QA support, and structured evidence exports.

Researchers + CROs

Build structured multimodal datasets across morphology, Flow, review labels, and disease context.

Value

Cleaner cohort review, translational research support, and reusable evidence packets.

Validation stage

Built with real reviewer feedback, not demo-only assumptions.

NanoCure AI is being evaluated on de-identified human patient-slide workflows and reviewed by board-certified pathologists. The current pilot is focused on workflow value, evidence organization, reviewer feedback, and traceability before clinical claims are made. Histology review is under development as a coming-soon expansion of the same evidence-packet approach.

De-identified patient-slide testing

Used to harden morphology review, case packet design, and workflow fit.

Pathologist-centered design

Reviewer actions, evidence tables, uncertainty, and source mapping are central to the product.

Research-to-product path

The pilot gives qualified teams a controlled way to evaluate value while NanoCure AI strengthens traceability and regulatory readiness.

60-day pilot program

Evaluate NanoCure AI on your real hematology workflow.

We are opening controlled pilot access for qualified teams that want to evaluate structured morphology and Flow FCS evidence review without replacing core lab hardware.

Contact help@nanocureai.org Existing User Sign In

Include institution/organization, role, intended use, expected workflow volume, and whether you want Morphology Review, Heme Malignancy Screen, Flow FCS Review, or both.

✓

Pathology and hematopathology groupsTeams reviewing blood smears, marrow material, Flow Cytometry, or hematologic malignancy cases.

✓

Diagnostic centers and lab directorsOrganizations that need structured review evidence, QA support, and workflow visibility.

✓

Academic researchers and CROsTeams building hematology datasets, translational studies, or multimodal review workflows.

Request accesshelp@nanocureai.org

Approved users receive pilot access for research/workflow evaluation.